Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TTK | P33981 | 2/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 4/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672674 | 0.75 | IDO1 (0.78) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL1754216 | 0.72 | IDO1 (0.56) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL855531 | 0.70 | ALDH1A1 (1.00) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL30768403 | 0.70 | ALDH1A1 (1.00) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL2969026 | 0.69 | ESR1 (0.41) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL17610247 | 0.68 | IDO1 (0.60) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL16937122 | 0.68 | IDO1 (0.71) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL17178615 | 0.67 | ALDH1A1 (0.92) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL7619575 | 0.67 | ITK (0.51) | IDO1KDM4EGAAALDH1A1TTK | |
| SCHEMBL10533662 | 0.66 | IDO1 (0.74) | IDO1KDM4EGAAALDH1A1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398911-A2 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | Memorial Sloan Kettering Cancer Center (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024123818-A1 | FUNCTIONALIZED COLLOIDAL SILICA AND METHODS OF PRODUCTION | W.R. GRACE & CO.-CONN (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4370701-A1 | TEXTILES DERIVED FROM FOOD WASTE AND PROCESSES OF MAKING THEREOF | Alt Tex Inc. (CA) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024102441-A1 | PROCESSING AID FORMULATION AND POLYOLEFIN FILMS MADE THEREFROM | Amcor Flexibles North America, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024097945-A1 | PRODRUGS FOR MITOCHONDRIAL CALCIUM UPTAKE INHIBITORS | CORNELL UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024077087-A2 | M24B AMINOPEPTIDASE INHIBITORS FOR CARDS INFLAMMASOME ACTIVATION | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240100191-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024015641-A1 | SMALL MOLECULE FOR TREATMENT OF CANCER OF THE APPENDIX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4304594-A1 | HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS | Germanas, Juris (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024006287-A2 | ANTIVIRAL COMPOUNDS USEFUL AGAINST SARS-COV-2 | UNIVERSITY OF KANSAS (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2009070420-A1 | METAL ALKOXIDES, APPARATUS FOR MANUFACTURING METAL ALKOXIDES, RELATED METHODS AND USES THEREOF | APPLIED NANOWORKS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009058377-A1 | LIGANDS SPECIFIC FOR CANNABINOID RECEPTOR SUBTYPE 2 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-2035005-A2 | THERAPY USING CYTOKINE INHIBITORS | Kemia, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009002873-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008153633-A2 | PRODUCT CONTAINING MONOMER AND POLYMERS OF TITANYLS AND METHODS FOR MAKING SAME | APPLIED NANO WORKS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008124072-A1 | PALMEROLIDES: METHODS OF PREPARATION AND DERIVATIVES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007146712-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007075896-A2 | HETEROCYCLIC CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007056016-A2 | BISAMIDE CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100191-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | BRD4, BICRA, BRDT | IDO1 3988/4885KDM4E 924/4885GAA 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.